Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Januar 2019

Planlagt Fastgjort Låst Flyttet Genmab
2.8k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    peter12
    wrote on sidst redigeret af
    #952

    ER der nogen der kender Melflufen https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=9&cad=rja&uact=8&ved=2ahUKEwib2PWByfTfAhXJDywKHeDtDkYQFjAIegQIBBAC&url=https%3A%2F%2Fwww.oncopeptides.se%2Fen%2Fwp-content%2Fuploads%2Fsites%2F2%2F2019%2F01%2Foncopeptides-jpm-2019-3.pdf ? Kan se at der køre forsøg med dara ...

    1 Reply Last reply
    0
    • BulderB Offline
      BulderB Offline
      Bulder
      wrote on sidst redigeret af
      #953

      https://www.ashclinicalnews.org/on-lo cation/good-news-horizon-melflufen-induces-response-heavily-refractory-myeloma/ https://netdoktor.dk/medicin/skema/cytostatika.htm

      1 Reply Last reply
      0
      • BulderB Offline
        BulderB Offline
        Bulder
        wrote on sidst redigeret af
        #954

        prøver igen https://www.ashclinicalnews.org/on-location/good-news-horizon-melflufen-induces-response-heavily-refractory-myeloma/

        1 Reply Last reply
        0
        • P Offline
          P Offline
          peter12
          wrote on sidst redigeret af
          #955

          De kunne da hurtig blive spist 😉

          1 Reply Last reply
          0
          • K Offline
            K Offline
            kkjoel
            wrote on sidst redigeret af
            #956

            Sukkeralf (eller andre der har faglig viden omkring dette:), fra ADC Therapeutics hjemmeside, som du så venligt linkede til i går (om ADCT-301 interim data på 113 HL patienter i ph Ia/Ib):
            "In HL patients with a median of five prior lines of therapy and no other approved therapy options, the overall response rate was 86.5 percent, including a 43 percent compl
            ete response rate,.."

            1 Reply Last reply
            0
            • K Offline
              K Offline
              kkjoel
              wrote on sidst redigeret af
              #957

              Som lægmand drister jeg mig til at spørge: Er dette ikke vildt imponerende tal i 6. linje.. det er vel ikke normalt at man kan få en så høj responsrate (specielt CR - kræft ikke målbar længere - på næsten halvdelen) hos patienter, der har prøvet så mange andre behandlinger
              først?

              1 Reply Last reply
              0
              • K Offline
                K Offline
                kkjoel
                wrote on sidst redigeret af
                #958

                Og hvordan ville man have stillet sig, hvis tallene havde været 1. linje.. det ville være så fedt hvis du kunne sige lidt generelt (vedr. kræft bredt og/eller specifikt HL/MM) omkring sammenhængen mellem muligheden for "dyb" respons og hvilken linje man behandler?

                1 Reply Last reply
                0
                • K Offline
                  K Offline
                  kkjoel
                  wrote on sidst redigeret af
                  #959

                  Og skal minde om at GEN ejer 25% af rettighederne.. så GO ADCT!

                  1 Reply Last reply
                  0
                  • P Offline
                    P Offline
                    peter12
                    wrote on sidst redigeret af
                    #960

                    Det lyder som et meget potent stof 😉 Og desværre mange patienter

                    1 Reply Last reply
                    0
                    • K Offline
                      K Offline
                      kkjoel
                      wrote on sidst redigeret af
                      #961

                      Her linket til ADC Therapeutics igen https://adctherapeutics.com/

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #962

                        @Bulder if you are interested in Melflufen , i read this presentation earlier https://www.oncopeptides.se/en/2019-j-p-morgan-health-care-conference-presentation/

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #963

                          @kkjoel i imagine @Sukkeralf posted that link for the news on ADCT-601 , which they develop alone if i am correct

                          1 Reply Last reply
                          0
                          • E Offline
                            E Offline
                            E_L
                            wrote on sidst redigeret af
                            #964

                            based 301 data at ASH18 they plan a PhII trial in 2019

                            1 Reply Last reply
                            0
                            • K Offline
                              K Offline
                              kkjoel
                              wrote on sidst redigeret af
                              #965

                              Yes, you're probably right. But GEN only has part in ADCT-301, so that's why I focused that direction..

                              1 Reply Last reply
                              0
                              • K Offline
                                K Offline
                                kkjoel
                                wrote on sidst redigeret af
                                #966

                                Have you got any thoughts on response rates on a late 6. line? (It was probably discussed here after ASH.) And any insights into correlation between possibility for "deep" response and how far down treament-regime one is? (maybe also that was discussed here after ASH..)

                                1 Reply Last reply
                                0
                                • K Offline
                                  K Offline
                                  kkjoel
                                  wrote on sidst redigeret af
                                  #967

                                  Ahhhh, ADCT-601 binder til AXL.. så osse derfor specifkt interessant i GEN regi (enapotamab vedotin)

                                  1 Reply Last reply
                                  0
                                  • K Offline
                                    K Offline
                                    kkjoel
                                    wrote on sidst redigeret af
                                    #968

                                    Så eftersom begge stoffer binder til AXL, ligner det derfor spørgsmålet om det er ADCTs eller GENs cellegift der er den bedste/kan fåes til at virke bedst?

                                    1 Reply Last reply
                                    0
                                    • K Offline
                                      K Offline
                                      kkjoel
                                      wrote on sidst redigeret af
                                      #969

                                      Hvor ADCT har deres egen gift, mens GENs kommer fra Seatlle Genetics.

                                      1 Reply Last reply
                                      0
                                      • D Offline
                                        D Offline
                                        dohk
                                        wrote on sidst redigeret af
                                        #970

                                        Linker teknologien er rigtig vigtig. Linkeren kløves når ADCen transporteres ind i cellen og giften frigives. Der har været problemer med bivirkninger fordi linkeren kløves for tidligt...husker i hvert fald at immunogen havde problemer. SGEN har masser af validering af deres teknologi, så nok derfor Genmab kigger mod dem.

                                        1 Reply Last reply
                                        0
                                        • D Offline
                                          D Offline
                                          dohk
                                          wrote on sidst redigeret af
                                          #971

                                          Kan ikke huske hvilken linker teknologi ADC technology bruger og hvilken grad af validering den har.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger